Atlas Trials

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

Clinical trial NCT04066244 · TERMINATED

Trial details

NCT number
NCT04066244
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Amyotrophic Lateral Sclerosis
Start date
2019-12-30
Primary completion
2024-02-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.